CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 215 enrolled
Drug / intervention
Risperidone +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00423878
NCT00423878Phase 4Completed
CompareCT.gov

Clinical Management of Metabolic Problems in Patients With Schizophrenia

National Institute of Mental Health (NIMH)·interventional·Posted Jan 18, 2007·Updated Nov 2, 2016

In Brief

A Phase 4 clinical trial evaluating Risperidone, Olanzapine, and 2 other interventions for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 215 participants across 28 sites.

Detailed Summary

The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 18, 2007
Enrollment StartJan 1, 2007
Primary CompletionOct 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.5 years ago

Interventions

Risperidonedrug

Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study

Olanzapinedrug

Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study

Quetiapinedrug

Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study

Aripiprazoledrug

Switching medication to aripiprazole for schizophrenia for up to 6 months in study